和黃醫藥(00013.HK):沃瑞沙®(賽沃替尼/savolitinib)按現行條款成功續約中國國家醫保藥品目錄
格隆匯11月28日丨和黃醫藥(00013.HK)公吿,經過與中國國家醫療保障局("國家醫保局")的醫保續約,沃瑞沙®(ORPATHYS®,賽沃替尼)將繼續獲納入自2025年1月1日起生效的新版《國家基本醫療保險、工傷保險和生育保險藥品目錄》("醫保藥品目錄"),並維持與現行兩年期協議相同的條款。
沃瑞沙®是一種強效、高選擇性的口服MET酪氨酸激酶抑制劑("TKI")。其於2021年6月在中國獲附條件批准,用於治療特定的MET外顯子14跳躍突變的非小細胞肺癌患者。中國肺癌患者人數佔全世界肺癌患者總數的三分之一以上。在全球非小細胞肺癌患者中,約有2%-3%的患者伴有MET外顯子14跳躍突變。
沃瑞沙®於2023年3月1日首次獲納入醫保藥品目錄。中國政府高度重視改善人民羣眾用藥的可負擔性。截至2023年底,基本醫療保險參保人數為13.3億人,參保率穩定在95%左右。醫保藥品目錄每年進行調整,獲納入目錄的藥品每兩年重新進行續約。國家醫保局每年召集一個廣泛的專家網絡,包括醫學專家、藥學專家、藥物經濟學專家和基金測算專家等,對創新藥物准入醫保藥品目錄進行更新和調整。乙類藥物(包括創新腫瘤藥物)的報銷要求患者根據其居住省份或參加的醫療保險類型,支付不同比例的自付額。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.